Tomas L. Lindahl

Tomas Lindahl

Group leader of the Hemostasis Research Group at Department of Biomedical and Clinical Scienes. Professor in Clinical Chemistry, MD and senior consultant. Started in hemostasis research as PhD student at Karolinska Institute in Stockholm 1985, PhD 1989. I am doing research in Linköping since 1993, main sponsors at present are the Swedish Research Council, the Swedish Heart-Lung Foundation, Linköping University and Region Östergötland.

Haemostasis research – twinning basic and clinical research

In a healthy individual the blood is maintained in a flowing state during its passage through the vascular system, nevertheless always ready to rapidly form a hemostatic plug that will prevent unrestricted bleeding when a vessel is ruptured.

The primary events of the hemostatic response include adhesion of platelets to exposed collagen in the damaged vessel wall, and the subsequent activation of the adhered platelets; thus facilitating the recruitment of more platelets to the damaged area. These platelets form a platelet plug that initially stops the bleeding. The second stage in the hemostatic plug formation is the coagulation process, initiated by exposed tissue factor on subendothelial cells in the vessel wall. Coagulation is driven through a complex enzymatic pathway that involves several zymogene-to-enzyme conversion steps which allows the reaction to undergo great intrinsic amplification.

The many steps are strictly regulated and counter-acted by specific inhibitors on the surface of- and released by the adjacent cells in the intact vessel wall. The final step in this cascade is the conversion of soluble fibrinogen into an insoluble fibrin network; i.e. coagulation. The coagulation process is accelerated by activated platelets and will ultimately form a stabilizing fibrin network that will secure the platelet plug until the vessel wall can be restored.

There are many components in the vascular system that have important roles to play in both hemostasis and thrombosis; endothelium, platelets, leukocytes, immune system and the plasma coagulation system, to name the most significant. Another very important factor not to be overlooked is the constant movement of the blood throughout the vasculature. In fact, the rate of blood flow and the resulting shear forces have proved to be a key regulator of hemostatic function via the platelet and leukocyte interaction with components in the vessel wall.

In the healthy human, all these components work in concert in an interlinked system to rapidly achieve hemostasis; i.e. to stop bleeding after vessel injury.

However, when components in the vasculature or blood is affected by a state of disease or other external factors, the delicate balance of the hemostatic system may be disturbed and lead to unwanted and potentially harmful thrombosis or bleeding.

Cardiovascular disease is the predominant cause of death in the developed countries; therefore, cardiovascular research is one of the most important areas within the medical field.

Main Areas of Research

The role of platelets in haemostais and cardiovascular diseases

  • How do ruptured arteriosclerotic plaques initiate platelet adhesion, activation, and coagulation?
  • How is propagation of coagulation accomplished and how is thrombus growth limited?
  • How is activation of platelets counteracted and balanced?
  • Effects of heparinoids on platelet activation
  • Effects of novel anticoagulants on platelet activation

Coagulation – clinical studies

  • Biomarkers in covid-19 for mortality and thrombosis
  • Biomarkers in the middle-aged population for arteriosclerosis and cardiovascular disease- a substudy in the large multi-center Swedish CArdioPulmonary bioImage Study (SCAPIS).
  • Risk factors in venous thrombosis
  • Oral anticoagulation with warfarin and NOACs – from genes to treatment
  • Thrombin generation in health and disease

About me


  • Group leader of the Hemostasis Research Group at Linköping University
  • Proprefekt for research at Department of Experimental and Clinical Medicine
  • Professor in Clinical Chemistry
  • MD and senior consultant
  • Started in hemostasis research as PhD student at Karolinska Institute in Stockholm 1985, PhD 1989.
  • I am doing research in Linköping since 1993, main sponsors at present are the Swedish Research Council, the Swedish Heart-Lung foundation, Linköping University and Region Östergötland.
  • I am main tutor for 2 PhD students (both are MDs) and have been main tutor for 9 PhD students, latest dissertation Oct. 2018.
  • Citation analysis.  Note; changed family name from Carlsson to Lindahl 1987, added middle initial L. ca 1990 to avoid being mixed up with Tomas Lindahl, the Nobel Prize winner in chemistry 2015. As of April 2020- Citations 4235, 214 publications, Average citations per item 19.8, h-index 33 (Web of Science).


  • Member of board of the Swedish Society on Thrombosis and Haemostasis (
  • Chairman of the expert group on coagulation of EQUALIS (External Quality Assurance of Laboratory Medicine in Sweden)
  • Member of the Research Council of the Swedish Heart-Lung Foundation
  • National representative in EHTA (European Haemostasis and Thrombosis Alliance)



Lämna ett svar